Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set

K-Number: K162959 · 2017-01-04

ApplicantDiaSorin, Inc.
Decision Date2017-01-04
Product CodeLSE
Advisory CommitteeMI
DecisionSubstantially Equivalent

Device Summary

LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set is the device name listed in this FDA 510(k) record. The listed applicant is DiaSorin, Inc.. It received FDA 510(k) clearance on 2017-01-04 under 510(k) number K162959. The device is classified under product code LSE. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set?

LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set is a medical device that received FDA 510(k) clearance on 2017-01-04. The listed applicant is DiaSorin, Inc.. The 510(k) number is K162959.

When did LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set receive FDA 510(k) clearance?

LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set received FDA 510(k) clearance on 2017-01-04, under 510(k) number K162959.

Who is the listed applicant for LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set?

The FDA 510(k) record lists DiaSorin, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set?

The FDA product code for LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set is LSE.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT06955793Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech RepublicAVAILABLE

Other records listing DiaSorin, Inc. as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

PMA P250039ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGMPMA P220034ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGGK260770LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteXPMA P180047TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSISPMA P190017Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)PMA P180049Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)

View all 43 devices →

Related Devices (Code: LSE)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K233606ADVIA Centaur EBV-VCA IgMBiokit, S.A.K162961LIAISON® VCA IgG and LIAISON® VCA IgG Serum Control Set; LIAISON® EBNA IgG and LIAISON® EBNA IgG Serum Control SetDiaSorin, Inc.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑